» Articles » PMID: 37134105

Parkin-mediated Mitophagy is Negatively Regulated by FOXO3A, Which Inhibits Plk3-mediated Mitochondrial ROS Generation in STZ Diabetic Stress-treated Pancreatic β Cells

Overview
Journal PLoS One
Date 2023 May 3
PMID 37134105
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus (DM) is one of the most researched metabolic diseases worldwide. It leads to extensive complications such as cardiovascular disease, nephropathy, retinopathy, and peripheral and central nervous system through an inability to produce or respond to insulin. Although oxidative stress-mediated mitophagy has been reported to play an important role in the pathogenesis of DM, specific studies are still lacking as well as remain highly controversial. Here, we found that Parkin-mediated mitophagy in pancreatic β cells under streptozotocin (STZ)-diabetic stress was induced by Polo-like kinase 3 (Plk3) and inhibited by the transcription factor Forkhead Box O3A (FOXO3A). STZ stress induces mitochondrial recruitment of Parkin through Plk3-mediated mitochondrial reactive oxygen species (ROS) generation, which causes pancreatic cell damage. Conversely, FOXO3A acts as negative feedback to prevent diabetic stress by inhibiting Plk3. Meanwhile, antioxidants including N-acetylcysteine (NAC) and natural COA water scientifically block these mitochondrial ROS and mitochondrial recruitment of Parkin by inhibiting Plk3. Through a 3D organoid ex vivo model, we confirmed that not only ROS inhibitors but also mitophagy inhibitory factors such as 3-MA or Parkin deletion can compensate for pancreatic cell growth and insulin secretion under STZ diabetic stress. These findings suggest that the Plk3-mtROS-PINK1-Parkin axis is a novel mitophagy process that inhibits pancreatic β-cell growth and insulin secretion and FOXO3A and antioxidants may provide new alternatives for effective diabetes treatment strategies in the future.

Citing Articles

Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and β-cell function in NAFPD by inhibiting MST1-Foxo3a signalling pathway.

Zhang C, Li J, Wang L, Ma J, Li X, Wu Y Cell Prolif. 2024; 58(3):e13764.

PMID: 39413003 PMC: 11882769. DOI: 10.1111/cpr.13764.


SIRT3 alleviates painful diabetic neuropathy by mediating the FoxO3a-PINK1-Parkin signaling pathway to activate mitophagy.

Yang J, Yu Z, Jiang Y, Zhang Z, Tian Y, Cai J CNS Neurosci Ther. 2024; 30(4):e14703.

PMID: 38572816 PMC: 10993345. DOI: 10.1111/cns.14703.

References
1.
Schofield J, Schafer Z . Mitochondrial Reactive Oxygen Species and Mitophagy: A Complex and Nuanced Relationship. Antioxid Redox Signal. 2020; 34(7):517-530. DOI: 10.1089/ars.2020.8058. View

2.
Gimenez V, de Las Heras N, Lahera V, Tresguerres J, Reiter R, Manucha W . Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases. Front Aging Neurosci. 2022; 14:888292. PMC: 9204094. DOI: 10.3389/fnagi.2022.888292. View

3.
Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B . Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011; 60(6):1770-8. PMC: 3114402. DOI: 10.2337/db10-0351. View

4.
Kim J, Lee S, Yi S, Han S, Kim S, Lee J . WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation. Cell Res. 2016; 27(2):274-293. PMC: 5339850. DOI: 10.1038/cr.2016.148. View

5.
Brownlee M . Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865):813-20. DOI: 10.1038/414813a. View